Cascone, Tina <br/><br/>
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.  [electronic resource] 

 -  Journal of cellular physiology  Sep 2008 
 - 698-707 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-4652 
<br/><br/><label>Standard No.: </label>10.1002/jcp.21444  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Cell Line, Tumor--drug effects<br/>Cetuximab<br/>Dose-Response Relationship, Drug<br/>Drug Combinations<br/>Drug Synergism<br/>Enzyme Activation<br/>ErbB Receptors--antagonists & inhibitors<br/>Gefitinib<br/>Humans<br/>Mitogen-Activated Protein Kinases--genetics<br/>Piperidines--pharmacology<br/>Proteasome Endopeptidase Complex--metabolism<br/>Proteasome Inhibitors<br/>Proto-Oncogene Proteins c-akt--genetics<br/>Pyrazines--pharmacology<br/>Quinazolines--pharmacology<br/>Signal Transduction--physiology